Skip to main content

Advertisement

Download PDF

The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process

BMC Research Notes volume 11, Article number: 620 (2018) Cite this article

Abstract

Objective

This manuscript aims to provide an overview of the unique considerations and best practice principles associated with the manufacture of human viral challenge agents.

Results

Considerations are discussed on the entire process from strain and viral source selection through manufacturing, safety and efficacy testing. The human viral challenge (HVC) model is an important tool to help accelerate the drug development process but producing viruses suitable for use in the model presents a unique set of challenges. There are many case by case decisions and risk assessments to consider and no clear international standard to produce viruses for this purpose. The authors present challenge virus manufacturing considerations from the current literature, regulatory guidance and their own direct experience in producing challenge viruses. The use of these viral stocks in clinical studies, as published in peer-reviewed journals, is also briefly described.

Introduction

Edward Jenner performed possibly the first documented Human Viral Challenge (HVC) study in 1796 [1]; since then such studies have become established. A range of challenge agents (CAs) including viruses, toxins, allergens, bacteria and fungi have been administered to people to induce a physiological or pathological effect [2] under various regulatory frameworks. The US regulators consider CAs like drugs, and thus studies performed in the US are conducted within the FDA (US Food and Drug Administration) Investigational New Drug (IND) framework. The UK and the EU regulators don’t, resulting in less clarity regarding the guidance to follow [3, 4]. When a CA is used in the UK, not in conjunction with an investigational medicinal product (IMP), a study is classified as a clinical “study” and not as a clinical “trial” as defined in the Medicines Regulation 536/2014 [5].

Considering the lack of specific guidance on production of viral CAs, this publication aims to provide some guidance to others considering producing CAs by addressing the key points we considered in the production of our respiratory virus CAs. We incorporate reviews of the latest regulatory and GMP guidelines, the scientific literature and our own discussions with the FDA and MHRA. The authors have conducted multiple HVC studies with over 2500 volunteers using numerous different challenge viruses including influenza, respiratory syncytial virus (RSV) and human rhinovirus (HRV).

Main text

Safety of challenge viruses is of paramount importance and when selecting a suitable virus, hence a thorough literature review of the naturally occurring pathogenicity of the virus and potential risks should be undertaken. As an example; (H1N1) A/California/7/2009-like (pdm09-like) influenza virus isolates may have two key mutations in the Haemagglutinin receptor binding site, D222G and D222N. Both lead to greater tropism for the lower respiratory tract and are associated with severe clinical outcome [6]. Viral genome sequencing ensures that mutations affecting pathogenicity and virulence, or those that may confer resistance to antiviral therapy are not present in the CA.

Different viral strains can be used and, based on the level of pre-existing immunity in subjects, be expected to result in differing pathogenic profiles. For viruses where the key correlates of protection are known, tests can be conducted to assess pre-existing immunity ensuring the virus produces a suitable pathogenic profile and importantly, evaluable endpoints. Sero-suitability of subjects may include testing of serum IgG, mucosal secretory IgA and T cell immunity [7,8,9] depending on the challenge agent of interest.

A challenge virus must be clinically relevant and present a similar pathogenic profile to that observed in a natural infection or, where appropriate, attenuated pathogenicity or disease exacerbation. For instance, rhinovirus types, A and C have been associated with asthma exacerbations, while Rhinovirus type B frequently induce a subtly different cytokine pathway leading to moderate asthma attack [10]. Wild-type viruses should always be used unless there are known risks of a severe clinical outcome. We choose viruses not deliberately attenuated but that produce symptoms consistent with clinically observed Acute Respiratory Infection (ARI) in a healthy population [11,12,13].

Manufacturing substrates can introduce mutations and the number of passages of the virus during manufacture should always be minimised. However, sequencing of isolates obtained during active infection in the model has shown that such mutations are rapidly selected out and thus may be of limited consequence [14].

Pre-production and upstream processing

Viral seed material can be obtained from several sources, including an existing good manufacturing practice (GMP)-produced virus inoculum, clinical isolates or generated via reverse genetics. Careful consideration should be taken as to the source of the material regarding documentation, e.g., isolate history.

Isolates can be obtained either from subjects who acquire an infection naturally (field isolates) or from subjects inoculated experimentally (experimental challenge isolates) where the donor shows a suitable pathogenic profile. All clinical isolates must be acquired from a reputable source. The donor should be in good health with a full medical history, free from cancer or chronic illness, HIV, Hepatitis B, Hepatitis C and HTLV; nor have received blood products to mitigate the risk of any unknown pathogens and transmissible spongiform encephalopathies (TSEs).

Field isolates would likely be sourced if an appropriate seed could not be obtained from a reputable provider of virus such as the World Health Organisation (WHO), Center for Disease Control (CDC) or European Centre for Disease Control (ECDC). An isolate from an experimentally infected volunteer has advantages, the health status and medical history are known in a great level of detail as well as when in the course of infection the isolate was obtained.

The use of reverse genetics to manufacture a virus removes the need for adventitious agent testing of the donor. The appropriate pathogenicity factors can be included or eliminated from these Genetically Modified Microorganisms (GMMs). When reverse genetics is used to produce a wild-type-like virus the pathogenicity profile should be like that of the naturally occurring strain. The GMM can be deliberately attenuated; NIBRG-14 is an attenuated version of a highly pathogenic influenza (bird flu) strain with the internal genes of A/PR/8/34 (a high-yield strain) and the hemagglutinin (HA) and neuraminidase (NA) genes of A/Vietnam/1194/04(H5N1) virus. The polybasic cleavage site of the HA, known to be related to high pathogenicity, is removed [15]. Such GMMs would not be expected to provide the full pathogenic profile of a wild-type clinical strain but could still provide useful information on the efficacy of a vaccine or therapy.

Viral seed material may require pre-production processing; such upstream processing would typically involve plaque purification, rate limiting dilution, filtration and possibly selective microbial treatment.

Whenever possible, a pilot stock would be produced and screened for a range of adventitious agents as determined by the risk assessment, and as a minimum sequenced to confirm identity.

Production and manufacturing

The manufacturing substrate will vary depending on the virus and range from embryonated eggs, cell culture and other in vivo methodologies. Each method poses challenges and risks to be assessed. Some challenge agents, including viruses and bacteria, can be propagated in Specific Pathogen Free (SPF) embryonated eggs with the advantages of low cost, ease of production and pathogen filter effect [16].

Most challenge viruses are propagated in cell culture. GMP cell lines must be fully qualified, their history and providence known; examples include Vero cells, MRC-5 cells and PerC6 cells [16,17,18,19]. Other cell lines can be used, but to reduce the risk of contamination by TSEs and latent pathogens they require extensive testing and traceability of all reagents used.

Manufacturing should be conducted in a GMP setting designed to minimise the risks involved in any production that cannot be brought to light through testing of the final product. As cited in the EU regulations [20], we consider that challenge agents should be produced on a campaign basis, which results in isolation of the CA manufacturing away from other products.

A GMP manufacturing facility should be audited both from a scientific and Quality Assurance perspective. The scientific audit determines knowledge of viral handling best practices and the Quality Assurance audit ensures appropriate regulatory requirements are met.

Any materials to be released formally from the facility must be accompanied by a copy of the complete batch record, a certificate of GMP compliance and a certificate of analysis.

Downstream processing and testing

There are different approaches to the downstream processing of a post-GMP production harvest, but all have the same final requirements. The virus must be as free as possible from all components used during the production that may affect its final aim, i.e. a suitable pathogenicity profile while ensuring that the safety of the volunteers inoculated are not put at risk. Any product produced in a mammalian cell line should have minimal residual host cell DNA content [17, 21].

Adventitious agent testing forms a critical and substantial part of the safety data required for a challenge virus stock. The stock must be tested for any adventitious agents that could reasonably be expected to contaminate it and potentially cause a safety risk to study subjects. We do not propose a definitive specific list of adventitious agents that one should test for as the appropriate testing strategy used will depend on a range of factors as well as the current opinion of the regulator. We simply describe the best practice principles that we applied in the manufacturing of our challenge viruses and give some examples in the hope of giving some guidance to others (see Additional file 1: Tables S1 and S2).

A diluent is required to dilute the challenge stock to an appropriate inoculum titre, ensuring stability in storage before use (see Additional file 1: Figure S1 for an example of a stabilised influenza challenge virus). It must be inert, manufactured under GMP conditions and shown to be sterile, free from mycoplasma, endotoxins and other adventitious agents.

The harvest should be diluted and filled into single-use vials under GMP conditions. We propose a minimum testing panel for the release of the product from the manufacturing facility before the full adventitious testing panel required before human use (see Additional file 1: Table S1). All packaging should be suitable for clinical use, inert to the product and tamper proof. All vials should be individually labelled to enable full traceability.

Risk assessment and literature reviews to consider potential adventitious agents that could contaminate the product during each stage of the process from seed virus collection, pre-production processing, production, through to final fill of the GMP manufactured product should be conducted. For our challenge viruses, we considered the potential risks from all of the raw materials and cell banks/eggs used and possible newly emerging agents at the time of manufacture. Testing included; sterility, microbial enumeration testing, Mycoplasma & Mycobacterium detection tests along with testing for non-specific viral contaminants by in vitro inoculation of indicator cells. Also, we conducted tests for the quantification of reverse transcriptase activity as well as extensive agent-specific molecular testing for a panel of contaminants including known human viruses of both chronic and acute infections as well as the list of other potential pathogen contaminants that were highlighted by the risk assessment.

Consideration should be given to the use of an animal model to check pathogenicity. However, for ethical considerations, it should only be used when it is sure to have good correlation with human disease and provide clear guidance for subsequent human studies.

We have characterised numerous new challenge viruses following manufacture via the HVC; these included respiratory syncytial virus [13], human rhinovirus-16 [12] and influenza A/Perth/9/2009 [H3N2] [11] determining their safety, pathogenic profile and the appropriate evaluable endpoints [12, 13, 22]. These challenge viruses have been used to test the efficacy of antiviral drugs or vaccines [9, 23,24,25,26,27,28,29] and also the virus-host interaction [8, 13, 30,31,32,33,34,35,36,37], each time gaining more data on the challenge virus performance. It is crucial to build an extensive database of evaluable endpoints, beyond the initial characterisation studies, so as to accurately predict future performance of the virus and power subsequent product-efficacy studies.

The production and testing of an influenza GMP challenge virus are shown schematically in Fig. 1.

Fig. 1
figure1

Summary of the production and testing of virus challenge agents

Full size image

Conclusion

There are numerous decisions to be made in the complex and specialized process of manufacturing a new challenge virus with each virus production creating a unique set of circumstances to consider. This is made harder by the lack of specific regulatory and technical guidance. Therefore, we used our own direct experience in producing viral challenge agents to present an overview of the considerations and the best practice principles involved in virus manufacture so that this may serve as an initial guide to others embarking on challenge agent production. We propose that applying the methodical risk-based approach discussed above will enable new viral challenge agents to be produced, like our own, in a scientifically robust and safe manner that gives reliable results and generates clear evaluable endpoints in the HVC model. This will in turn further expand the utility of the HVC model in evaluating the efficacy of antiviral compounds and vaccines or human host interactions.

Limitations of the manuscript

The authors acknowledge that, due to the lack of documented regulatory guidance specific to challenge virus production, the considerations and manufacturing options discussed are mainly based on the direct experience of the authors.

Abbreviations

ARI:

Acute Respiratory Infection

CAs:

Challenge agents

CDC:

Center for Disease Control

ECDC:

European Centre for Disease Control

GMP:

Good manufacturing practice

GMMs:

Genetically modified microorganisms

HA:

Hemagglutinin

NA:

Neuraminidase

HVC:

Human viral challenge model

FDA:

US Food and Drug Administration

IND:

Investigational New Drug

SPF:

Specific Pathogen Free

TSEs:

Transmissible spongiform encephalopathies

WHO:

World Health Organisation

References

  1. 1.

    Jenner E: An inquiry into the causes and effects of the Variolae vaccinae, a disease discovered in some of the western countries of England, particularly Gloucestershire, and known by the name of “The Cow Pox”. Reprinted by Milan: R Lier & Co, 1923:84 1798.

  2. 2.

    Darton TC, Blohmke CJ, Moorthy VS, Altmann DM, Hayden FG, Clutterbuck EA, Levine MM, Hill AV, Pollard AJ. Design, recruitment, and microbiological considerations in human challenge studies. Lancet Infect Dis. 2015;15:840–51.

  3. 3.

    Good clinical practice guide. 3rd ed. London: The Stationary Office; 2014.

  4. 4.

    The Rules Governing Medicinal Products in the European Union, Guidance on INPS and NIMPs 1 Eudralex 10.

  5. 5.

    Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC Text with EEA relevance. (Union E ed., vol. 536/2014 Brussels: Official Journal of the European Union; 2014.

  6. 6.

    Fullen D, Lambkin-Williams R. Risk factors associated with severe clinical outcomes of pandemic H1N1 infection. J Hum Virol Retrovirol. 2014. https://doi.org/10.15406/jhvrv.2014.01.00016.

  7. 7.

    Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Fargis S, Risos K, Powers JH, et al. Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A/H1N1 virus healthy human challenge model. MBio. 2016;7:e00417.

  8. 8.

    Wilkinson T, Li C, Chui C, Huang A, Perkins M, Liebner J, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, et al. Preexisting influenza specific CD4 T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012;18:274–80.

  9. 9.

    Lambkin-Williams R, Gelder C, Broughton R, Mallett CP, Gilbert AS, Mann A, He D, Oxford JS, Burt D. An intranasal proteosome-adjuvanted trivalent influenza vaccine is safe, immunogenic & efficacious in the human viral influenza challenge model. serum IgG & mucosal IgA are important correlates of protection against illness associated with infection. PLoS ONE. 2016;11:e0163089.

  10. 10.

    Tay H, Wark PA, Bartlett NW. Advances in the treatment of virus-induced asthma. Expert Rev Respir Med. 2016;10:629–41.

  11. 11.

    Fullen DJ, Noulin N, Catchpole A, Fathi H, Murray EJ, Mann A, Eze K, Balaratnam G, Borley DW, Gilbert A, Lambkin-Williams R. Accelerating influenza research: vaccines, antivirals, immunomodulators and monoclonal antibodies. the manufacture of a new wild-type H3N2 virus for the human viral challenge model. PLoS ONE. 2016;11:e0145902.

  12. 12.

    Fullen DJ, Murray B, Mori J, Catchpole A, Borley DW, Murray EJ, Balaratnam G, Gilbert A, Mann A, Hughes F, Lambkin-Williams R. A tool for investigating asthma and COPD exacerbations: a newly manufactured and well characterised GMP wild-type human rhinovirus for use in the human viral challenge model. PLoS ONE. 2016;11:e0166113.

  13. 13.

    DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, Harrison L, Meeking P, Mann A, Moane E, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2010;182:1305–14.

  14. 14.

    Sobel Leonard A, McClain MT, Smith GJ, Wentworth DE, Halpin RA, Lin X, Ransier A, Stockwell TB, Das SR, Gilbert AS, et al. Deep sequencing of influenza A virus from a human challenge study reveals a selective bottleneck and only limited intrahost genetic diversification. J Virol. 2016;90:11247–58.

  15. 15.

    Robertson JS, Engelhardt OG. Developing vaccines to combat pandemic influenza. Viruses. 2010;2:532–46.

  16. 16.

    FDA: Guidance for industry characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. Research CfBEa ed.: Office of Communication, Outreach and Development; 2010.

  17. 17.

    ICH: ICH harmonised tripartite guideline: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A(R1). In International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use: ICH; 1999.

  18. 18.

    PTC: Points to consider in the characterization of cell lines used to produce biologicals. Rockville, MD; 1993.

  19. 19.

    HO: Evaluation of cell substrates for the production of biologicals: revision of WHO recommendations. In Report of the WHO Study Group on cell substrates for the production of biologicals; 2000.

  20. 20.

    The Rules Governing Medicinal Products in the European Union. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/chapter_5.pdf.

  21. 21.

    CPMP: CPMP position statement on DNA and host cell proteins (HCP) impurities, routine testing verses validation studies. London; 1997.

  22. 22.

    Fullen DJ, Noulin N, Catchpole A, Fathi H, Murray EJ, Mann A, Eze K, Balaratnam G, Borley DW, Gilbert A, Lambkin-Williams R. Correction: accelerating influenza research: vaccines, antivirals, immunomodulators and monoclonal antibodies. The manufacture of a new wild-type H3N2 virus for the human viral challenge model. PLoS ONE. 2016;11:e0157211.

  23. 23.

    Cass L, Ito K, Charron C, Strong P, Norton C, Gilbert A, Lambkin-Williams R, Mann A, Rapeport G. RV568, a narrow spectrum kinase inhibitor (NSKI), inhibits virus induced nasal interleukin-8 (IL8) in the human viral challenge model where healthy adult male volunteers were experimentally inoculated with live respiratory syncytial virus. Eur Respir J. 1970;2013:42.

  24. 24.

    DeVincenzo J, Cehelsky J, Foote K, Nochur S, Vaishnaw A, Lambkin-Williams R, Meeking P, Mann A, Moane E, Studholme B, et al.: Early clinical evaluation of an RNA interference (RNAi) based therapy for respiratory syncytial virus (RSV) infection. Pediatr Acad Soc. 2007: 616295.

  25. 25.

    DeVincenzo J, Lambkin-Williams R, Wilkinson T, Cehelsky J, Nochur S, Walsh E, Meyers R, Gollob J, Vaishnaw A. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA. 2010;107:8800–5.

  26. 26.

    DeVincenzo JP, McClure MW, Symons JA, Fathi H, Westland C, Chanda S, Lambkin-Williams R, Smith P, Zhang Q, Beigelman L, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med. 2015;373:2048–58.

  27. 27.

    DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, McBride S, Lambkin-Williams R, Jordan R, Xin Y, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014;371:711–22.

  28. 28.

    McBride JM, Lim JJ, Burgess T, Deng R, Derby MA, Maia M, Horn P, Siddiqui O, Sheinson D, Chen-Harris H, et al. Safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza a challenge model: a phase 2 randomized trial. Antimicrob Agents Chemother. 2017. https://doi.org/10.1128/AAC.01154-17.

  29. 29.

    Pleguezuelos O, Robinson S, Fernandez A, Stoloff GA, Mann A, Gilbert A, Balaratnam G, Wilkinson T, Lambkin-Williams R, Oxford J, Caparros-Wanderley W. A synthetic influenza virus vaccine induces a cellular immune response that correlates with reduction in symptomatology and virus shedding in a randomized phase Ib live-virus challenge in humans. Clin Vaccine Immunol. 2015;22:828–35.

  30. 30.

    Bagga B, Woods CW, Veldman TH, Gilbert A, Mann A, Balaratnam G, Lambkin-Williams R, Oxford JS, McClain MT, Wilkinson T, et al. Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals. Antivir Ther. 2013;18:785–91.

  31. 31.

    Burke TW, Henao R, Soderblom E, Tsalik EL, Thompson JW, McClain MT, Nichols M, Nicholson BP, Veldman T, Lucas JE, et al. Nasopharyngeal protein biomarkers of acute respiratory virus infection. EBioMedicine. 2017;17:172–81.

  32. 32.

    Killingley B, Enstone JE, Greatorex J, Gilbert AS, Lambkin-Williams R, Cauchemez S, Katz JM, Booy R, Hayward A, Oxford J, et al. Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study. J Infect Dis. 2012;205:35–43.

  33. 33.

    McClain MT, Henao R, Williams J, Nicholson B, Veldman T, Hudson L, Tsalik EL, Lambkin-Williams R, Gilbert A, Mann A, et al. Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge. Clin Exp Immunol. 2016;183:441–51.

  34. 34.

    McClain MT, Park LP, Nicholson B, Veldman T, Zaas AK, Turner R, Lambkin-Williams R, Gilbert AS, Ginsburg GS, Woods CW. Longitudinal analysis of leukocyte differentials in peripheral blood of patients with acute respiratory viral infections. J Clin Virol. 2013;58:689–95.

  35. 35.

    Wilkinson T, Pleguezuelos O, Robinson S, Stoloff G, Lambkin-Williams R, Oxford J, Mann A, Gilbert A, Caparros-Wanderley W. Induction of protective T cell immunity against influenza using a novel peptide vaccine. Eur Respir J. 2012;40:P2534.

  36. 36.

    Woods CW, McClain MT, Chen M, Zaas AK, Nicholson BP, Varkey J, Veldman T, Kingsmore SF, Huang Y, Lambkin-Williams R, et al. A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2. PLoS ONE. 2013;8:e52198.

  37. 37.

    Zaas AK, Chen M, Varkey J, Veldman T, Hero AO 3rd, Lucas J, Huang Y, Turner R, Gilbert A, Lambkin-Williams R, et al. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe. 2009;6:207–17.

Download references

Authors’ contributions

AC, DF, NN, AM, AG and RLW all contributed significantly to the process design and conduct of the manufacture and characterization of hVIVO’s CAs. AC and DF led the production of hVIVO’s most recent CA and provided the first draft of the manuscript. All authors contributed to the further iterations of the manuscript. RLW edited the manuscript to comply with publication guidelines of the journal and advised/provided oversight throughout the process of the manufacture of hVIVO’s CAs. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank the other employees of hVIVO Services Ltd for their support while characterising the viruses and also while writing this manuscript.

Competing interests

All authors at the time of writing this manuscript were full-time employees of hVIVO Services Ltd., which is part of hVIVO PLC. DF left and joined University College London and was a full-time employee of that University during the final reviews of the manuscript. No author had any competing interests.

Availability of data and materials

All data generated or analysed during this study are included in this published article [and its Additional information files].

Consent to publish

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

All authors at the time of writing this manuscript were full-time employees of hVIVO Services Ltd., which is part of hVivo PLC. DF left and joined University College London and was a full-time employee of that University during the final reviews of the manuscript. hVivo PLC funded this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Author notes

  1. Andrew P. Catchpole and Daniel J. Fullen have contributed equally to this work

Affiliations

  1. hVivo Services Ltd, London, UK
    • Andrew P. Catchpole
    • , Daniel J. Fullen
    • , Nicolas Noulin
    • , Alex Mann
    • , Anthony S. Gilbert
    •  & Rob Lambkin-Williams
Authors
  1. Andrew P. Catchpole
    View author publications
    You can also search for this author in
  2. Daniel J. Fullen
    View author publications
    You can also search for this author in
  3. Nicolas Noulin
    View author publications
    You can also search for this author in
  4. Alex Mann
    View author publications
    You can also search for this author in
  5. Anthony S. Gilbert
    View author publications
    You can also search for this author in
  6. Rob Lambkin-Williams
    View author publications
    You can also search for this author in

Corresponding author

Correspondence to Andrew P. Catchpole.

Additional file

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Catchpole, A.P., Fullen, D.J., Noulin, N. et al. The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process. BMC Res Notes 11, 620 (2018). https://doi.org/10.1186/s13104-018-3636-7

Download citation

Keywords

  • Human viral challenge model
  • HVC
  • Experimental challenge
  • Viral challenge
  • Good manufacturing process
  • GMP
  • Adventitious agent testing
  • Clinical trials
  • Influenza
  • Human rhinovirus
  • Respiratory syncytial virus
  • Asthma

BMC Research Notes

ISSN: 1756-0500

Contact us